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A gene coding for human stefin B was synthesized by the solid-phase phosphite method and cloned in the pUC8 cloning 
vector. The insert with the verified DNA sequence was subcloned into two expression vectors and expressed in E. coli 
as a fusion protein with &galactosidase and as a native protein. The CNBr cleaved fusion protein and the native recombi- 
nant stefin B were inhibitory to papain and reacted with antibodies against human stefin B. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Stefin B is a protein inhibitor of the cysteine pro- 
teinases. It belongs to the stefin family of the 
cystatin superfamily [l]. It has been isolated from 
human spleen and liver and its amino acid se- 
quence has been fully determined [2,3]. Stefin B is 
distributed widely among the tissues and is mostly 
localized intracellularly as other stefins but it has 
also been found extracellularly [4]. Its role is 
generally accepted as a protector against the pro- 
teinases leaking from lysosomes. In order to obtain 
more of the protein for study of its interactions 
with cysteine proteinases and for further elucida- 
tion of its physiological functions we decided to 
clone the gene for stefin B and to produce the pro- 
tein using transformed bacteria. 
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2.1. Materials 
The enzymes used for the various experiments described 
below were purchased from Pharmacia (Uppsala) except he Se- 
quenase kit for DNA sequencing which was from the United 
States Biochemical Corporation. Protocols for standard pro- 
cedures were those as published [5], unless otherwise specified. 
2.2. Design of the synthetic gene 
Design of the synthetic gene was done with help of the pro- 
gram package ‘KLON’ (unpublished), written especially for this 
purpose. We inserted restriction sites to ease the future 
mutagenesis, obeyed the optimal codon usage of E. coli [6] and 
tried to avoid stable secondary structures. Conceptual fragmen- 
tation of the gene into the oligonucleotides was done with the 
program ‘REGEN’ as described [7]. 
2.3. Chemical synthesis, purification and phosphorylation of 
the oligonucleotides 
Oligonucleotides were synthesized with an Applied 
Biosystems 381A synthesizer using methyl phosphoramidites. 
Crude oligonucleotides were purified by reversed-phase HPLC 
on an Zorbax ODS column (4.6 mm x 25 cm) before the 
detritylation (chromatographic conditions: solvent A, 5% 
acetonitrile, 0.1 M trimethylammonium acetate in H20; solvent 
B, 80% acetonitrile; flow rate, 1 ml/min; gradient, O-50010 B in 
30 min). Final purification was achieved by gel electrophoresis 
on 15% polyacrylamide gel. The oligonucleotides were visua- 
lized by UV-shadowing, excised from the gel and eluted with 
water. Phosphorylation on the 5’-terminus was done with T4 
polynucleotide kinase. 
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2.4. Ligation of the synthetic gene into the plJC8 vector 
The phosphorylated oligonucleotides (20 pmol each, except 
in nos 1 and 16 at 40 pmol) were mixed in a total volume of 
35 gl in the 67 mM Tris-HCl, pH 8.0, 10 mM MgClz, heated at 
100°C for 2 min and cooled to room temperature for an hour. 
20 pmol of the BarnHI and Safl digested and dephosphorylated 
vector pUC8 (purchased from Pharmacia) was added, ATP to 
the final concentration of 1 mM and DTT to 10 mM. Ligation 
was carried out after the addition of the 1 U of Tq DNA ligase 
at 14°C for 16 h. 
2.5. Identification of the recombinant clone 
Competent cells (.I?. coli DHSa-purchased from BRL) 
prepared by the DMSO method [8] were transformed by the 
ligation mixture. Recombinant colonies were identified by the 
X-gal test. Restriction analysis of the mini preps cut with 
PstVKpnl identified the plasmids with the correct insert - 
pUC8-SB. Plasmid was sequenced by the Sequenase kit as sug- 
gested by the producer. 
2.6. Construction of expression vectors 
The gene for stefin B was excised from the pUCS-SB plasmid 
by digestion with BamHI and SalI, eluted from the 5% 
polyacrylamide gel and ligated into the pKP1500 expression 
vector (provided kindly by T. Miki and T. Imoto, Kyushu 
University, Japan, [9]) and into the pUR288 (provided by H.G. 
Gassen [lo]), treated previously with the same enzymes. 
2.1. Expression and purification of recombinant stefin B 
Cells, harboring pKP15OOSB plasmid were harvested 3 h 
after the induction with IPTG and lysed as described [ 111. 
Stefin B was isolated by means of affinity chromatography on 
carboxymethyl-papain Sepharose followed by the gel filtration 
on Superose 12 column [3]. For the amino acid sequence deter- 
mination the protein was isolated by HPLC using gradient of 
the acetonitrile/O.l% TFA. Cleavage with CNBr was done in 
16 h in 80% formic acid using weight ratio 1: 10 (CNBr/pro- 
tein) and the protein concentration 10mg/ml. The sample was 
lyophilized and twice evaporated with HzO. The inhibitory ac- 
tivity was determined against papain [12]. 
2.8. N-terminal amino acid sequence analysis 
Sequential Edman degradation was performed by the Ap- 
plied Biosystems (Foster City, CA) 470A protein sequencer by 
the analysis of the phenylthiohydantoin derivatives of amino 
acids on-line with 120A model HPLC of Applied Biosystems. 
2.9. Immunological detection 
Protein mixture was separated on the SDS-PAGE using the 
Phast system from Pharmacia and electrophoretically transfer- 
red onto the nitrocellulose membrane and treated with anti- 
human stefin B antibodies as described [13]. 
3. RESULTS AND DISCUSSION 
Since human stefin B is only 98 amino acids 
long, cloning via the synthetic gene appeared to be 
a reasonable approach. Moreover the protein only 
has two methionines positioned as the first two 
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amino acids and they would as such facilitate clon- 
ing as a fusion protein, producing by cleavage with 
CNBr almost intact protein. The inhibitory activity 
of the protein lacking the first two methionines 
should not be severely perturbed as was observed 
with the homologous rat cystatin fi [14]. 
The gene was assembled from 17 oligo- 
nucleotides as designated in fig. 1. Annealing of the 
oligonucleotides and ligation were done in one 
reaction mixture. We obtained approximately one 
half of the recombinant clones from which the cor- 
rect plasmids were identified by restriction 
analysis. After confirming the DNA sequence of 
the insert, we subcloned it into the pUR288 vector 
in frame at the C-terminus of the fi-galactosidase. 
The SDS-PAGE of the cell extract was blotted on 
a nitrocellulose membrane and the major protein 
band, corresponding to the iV& of the fusion pro- 
tein, was identified with an anti-human stefin B 
antibody (fig.2). The fusion protein was not in- 
hibitory active to papain. However, after cleavage 
of the whole protein extract with CNBr, the in- 
hibitory activity was generated, confirming that 
the protein without the N-terminal methionines is 
also active. 
As the next step the insert was transferred into 
the pKP1500 expression vector to 
[ 141. Both long and short forms exhibited 
the same inhibitory activity. Preliminary kinetic 
studies show that the natural and both recombi- 
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MetMetCysGlyAlaProSerAlaThrGlnProAlaThrAlaGluThrGlnHisIleAlaAspGlnValArgSer 
( __-_____________F1_________________)(_______________F2__________-_____)(-_____ 
GATCCATGATGTGTGGTGCTCCGTCTGCTACTCAGCCGGCTACTGCAGAAACTCAGCATATCGCTGACCAGGTTCGTTCT 
GTACTACACACCACGAGGCAGACGATGAGTCGGCCGATGACGTCTTTGAGTCGTATAGCGACTGGTCCAAGCAAGA 
( _______F9a_______)(______F9b________)(_________________FlO__-_______-___)(_ 
90 100 110 120 130 140 150 160 
GlnLeuGluGluLysTyrAsnLysLysPheProValPheLysAlaValSerPheLysSerGlnValValAlaGlyThrAsn 
--~~~----~3~~~----~~~~~---~)(~-~---~-_~~~~~~~~~~~~~~~~~~~~-~~~~~~---~~~)(___~~~~_- 
CAGCTGGAAGAGAAATACAACAAGAAATTCCCGGTTTTCAAAGCTGTAAGCTTCAAATCTCAGGTTGTTGCTGGTACCAAC 
GTCGACCTTCTCTTTA~GTTGTTCTTTAAGGGCCAAAAGTTTCGACATTCGAAGTTTAGAGTCCAACAACGACCATGGTTG 
_-_-______--_-_~~~__---_____---_)(_----_____----___~~2--___--_-____--_-____)(-___ 
170 180 190 200 210 220 230 240 
TyrPheIleLysValHisValGlyAspGluAspPheValHisLeuArgValPheGlnSerLeuProHisGluAsnLysPro 
_________~5__________________)(______---~~~~___~6~~~____________--__)(_-_--______ 
TACTTCATCAAAGTTCACGTTGGCGATGAAGACTTTGTTCACCTGCGCGTTTTCCAGTCTCTGCCGCACGAGAACAAACCG 
ATGAAGTAGTTTCAAGTGCAACCGCTACTTCTGAAACAAGTGGACGCGCAAAAGGTCAGAGACGGCGTGCTCTTGTTTGGC 
____________-_~~3_____-______-____)(-_-__~~~________~~~__-______---____--)(____-_ 
250 260 270 280 290 300 
LeuThrLeuSerAsnTyrGlnThrAsnLysAlaLysHisAspGluLeuThrTyrPhe x x 
__~7__--______--___)(--__-----___________~~~____-_______--____) 
CTGACTCTGTCCAACTACCAGACCAACAAAGCTAAGCACGACGAGCTGACCTACTTCTAGTAG 
GACTGAGACAGGTTGATGGTCTGGTTGTTTCGATTCGTGCTGCTCGACTGGATGAAGATCATCAGCT 
__-___F15-____-_______-_)(____-__--______-_____~~6______________--) 
Fig.1. Amino acid sequence of human stefin B and construction of thegene from 17 oligonucleotides. 
Fig.2. (A) SDS-PAGE under reducing conditions  the Phast system. Lanes: 1, human stefin B; 2 and 3, extract of E. coli 
DHSru/pUR288-SB after 3 hand before induction with IPTG; 4, extract of E. coli DHSa-pUR288 3h after induction; 5, molecular 
mass tandards. (B) Western blot of the gel from A with polyclonal anti-human stefin B antibodies. 
nant forms of stefin B have comparable Ki values. 
Thus, we have demonstrated the feasibility of 
expressing active stefin B in E. co/i via cloning by 
total gene synthesis. This system we are currently 
utilizing for site-directed mutagenesis to produce 
mutants that will be used to study the nature of the 
dimerization process in native stefin B [2,3] and 
the mechanism of action with its target enzymes. 
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